{"id":"klk2","name":"KLK2 (kallikrein-2)","symbol":"KLK2","route":"/targets/klk2/","asOf":"2026-09-06","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6363","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167751","uniprot":"https://www.uniprot.org/uniprotkb/P20151/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P20151","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2442","open-targets":"https://platform.opentargets.org/target/ENSG00000167751","civic":"https://civicdb.org/genes/3817/summary","oncokb":"https://www.oncokb.org/gene/KLK2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KLK2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=KLK2","depmap":"https://depmap.org/portal/gene/KLK2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000167751-KLK2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3817","omim":"https://www.omim.org/entry/147960"}],"products":[{"id":"pasritamig","name":"Pasritamig","status":"phase-3","modality":"Bispecific T-cell engager (KLK2×CD3)","route":"/drugs/pasritamig/"}],"trials":[{"id":"nct07225946","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT07225946","phase":"3","status":"recruiting"}],"pathways":[],"companies":["johnson-johnson"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}